- Conditions
- Guillain-Barre Syndrome
- Interventions
- Tanruprubart
- Drug
- Lead sponsor
- Annexon, Inc.
- Industry
- Eligibility
- 8 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Carlsbad, California + 18 more
Location Directory
Clinical trials in Durham, North Carolina
This page shows live ClinicalTrials.gov search results for Durham, North Carolina, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1918
Shown on this page
12
Current sort
Recently updated
Location scope
Durham, NC
Filters apply within this location only.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Showing 133–144 of 1,918 matching trials in Durham, NC.
Indexed local directory records.
Institutions in Durham
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Stored official records
Open in full search- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Interventions
- Cabozantinib, Casdatifan, Placebo
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 40 more
- Conditions
- Articular Cartilage Defect, Chondral Defect
- Interventions
- Bone Marrow Stimulation, autologous cultured chondrocytes on porcine collagen membrane
- Procedure · Biological
- Lead sponsor
- Vericel Corporation
- Industry
- Eligibility
- 17 Years to 65 Years
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 9
- States / cities
- Sacramento, California • Washington D.C., District of Columbia • Wichita, Kansas + 6 more
- Conditions
- Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Interventions
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 90
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 78 more
- Conditions
- Advanced Solid Tumors, CRC (Colorectal Cancer), Cancer, NSCLC (Non-small Cell Lung Cancer), PDAC - Pancreatic Ductal Adenocarcinoma
- Interventions
- ALTA3263, GnP, Midazolam, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin, cetuximab, mFOLFIRINOX, mFOLFOX6
- Drug
- Lead sponsor
- Alterome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 14
- States / cities
- Orlando, Florida • Tampa, Florida • Boston, Massachusetts + 7 more
- Conditions
- Stroke
- Interventions
- Telerehabilitation
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 27
- States / cities
- Downey, California • Irvine, California • Los Angeles, California + 20 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Not listed
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 28 more
- Conditions
- Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
- Interventions
- Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin, Echocardiography Test, Multigated Acquisition Scan, Pembrolizumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 258
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Dublin, California + 209 more
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- Not listed
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 9 more
- Conditions
- Plasma Cell Myeloma Refractory
- Interventions
- Acetaminophen, Carfilzomib, Dexamethasone, Diphenhydramine, Isatuximab SC-OBDS, Methylprednisolone, Montelukast
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Los Angeles, California • West Hollywood, California + 29 more
- Conditions
- Melanoma
- Interventions
- cemiplimab, fianlimab, relatlimab+nivolumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 106
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Tucson, Arizona + 87 more
- Conditions
- Advanced Cancer, Metastatic Cancer
- Interventions
- T-DXd
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Miami, Florida • Durham, North Carolina